辉瑞公司宣布，其研发的莱姆病候选疫苗Lb6v在针对五岁及以上人群的临床试验中展现出卓越的预防效果，疫苗效力超过70%。这一数据为抗击由蜱虫传播的莱姆病提供了新的希望。
研究结果表明，该疫苗在诱发人体免疫反应方面表现积极，能够有效降低莱姆病的感染风险。莱姆病若未及时治疗，可能引发神经系统及关节损伤等严重健康问题。
此次进展标志着辉瑞在传染病疫苗领域取得重要突破，有望填补当前莱姆病预防领域的空白。下一步，辉瑞将继续推进疫苗的临床研发与监管申报工作。
辉瑞公司宣布，其研发的莱姆病候选疫苗Lb6v在针对五岁及以上人群的临床试验中展现出卓越的预防效果，疫苗效力超过70%。这一数据为抗击由蜱虫传播的莱姆病提供了新的希望。
研究结果表明，该疫苗在诱发人体免疫反应方面表现积极，能够有效降低莱姆病的感染风险。莱姆病若未及时治疗，可能引发神经系统及关节损伤等严重健康问题。
此次进展标志着辉瑞在传染病疫苗领域取得重要突破，有望填补当前莱姆病预防领域的空白。下一步，辉瑞将继续推进疫苗的临床研发与监管申报工作。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.